By Chris Wack


Zai Lab Ltd. said on Wednesday that the National Reimbursement Drug List released by China's National Healthcare Security Administration has been updated to include two of its drugs, Qinlock and Nuzyra.

In March 2021, China's National Medical Products Administration approved Qinlock, also known as ripretinib, for the treatment of advanced gastrointestinal stromal tumor cases in adult patients who have received prior treatment with three of more kinase inhibitors, including imatinib.

In December 2021, the NMPA approved Nuzyra, also known as omadacycline, in both its oral and IV formulations, as Category 1 innovative drugs. Nuzyra was indicated to treat adults with community-acquired bacterial pneumonia and acute bacterial-skin and skin-structure infections.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-18-23 0837ET